ImCheck Therapeutics

ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, ImChecks first-in-class activating antibodies may be able to produce superior clinical results as compared to the first-generation of immune checkpoint inhibitors and, when used in combination, to overcome resistance to this group of agents. In addition, ImChecks antagonist antibodies are being evaluated as potential treatments for a range of autoimmune diseases. Co-founder of the Marseille Immunopole cluster, ImCheck benefits from support...

Antibodies,immuno-oncology,immune checkpoint modulators,auto-immunity,innate immunity,oncology,cancer,precision-based medicine,adaptative immunity,evictiontrial,ict01,and gamma-deltatcells

Imcheck therapeutics operates in the Biotechnology industry.

Imcheck therapeutics's revenue is 11m - 100m

Imcheck therapeutics has 51 - 200 employees.